Understanding Cancer Resistance
Targeting adaptive resistance mechanisms
with a novel dual-inhibitor approach
The Challenge
PIK3CA is one of the most frequently mutated genes across solid cancers including head and neck, lung, breast, and gastrointestinal malignancies.
Cancer cells develop resistance to PI3K inhibitors through mutations or activation of alternative signaling pathways, particularly EGFR, rendering single-target therapies ineffective over time.
Our Solution: MTX-531
A first-in-class small molecule dual inhibitor of PI3K and EGFR with PPARγ agonist activity, marking a new frontier in precision medicine.
The Advantage
By inhibiting EGFR alongside PI3K, MTX-531 mitigates the need to escalate dosages, thereby:
- Reducing exposure to toxicity
- Broadening the therapeutic index
- Enhancing anti-tumor activity
- Yielding more durable results
Novel Binding Mode Technology
MTX-531 employs innovative computational drug design, utilizing a unique flipped binding mode that allows a single molecule to selectively bind to both kinases:
- Dual Targeting: Simultaneously binds to both kinases utilizing different binding orientations
- Selective Inhibition: Targets PI3K and wild-type EGFR with low nanomolar potency
- PPARγ Agonism: Acts as a PPARγ agonist, significantly reducing therapy-induced hyperglycemia
- Superior Tolerability: Triple mechanism enables patients to stay on therapy longer with better outcomes
Key Innovation
This single-molecule triple-action approach (PI3K inhibition + EGFR inhibition + PPARγ agonism) eliminates the hyperglycemia liability common with PI3K inhibitors while blocking adaptive resistance pathways.
How MTX-531 Works
MTX-531's innovative triple mechanism blocks resistance pathways and improves tolerability
Cancer Resistance
Cancer cells activate PI3K and EGFR pathways to evade treatment and continue growth
MTX-531 Dual Action
Single molecule uses "flipped binding mode" to block both PI3K and EGFR simultaneously
PPARγ Agonism
MTX-531 activates PPARγ, significantly reducing therapy-induced hyperglycemia
Patient Benefit
Durable tumor regression with superior tolerability—patients stay on therapy longer
One Molecule, One PK Profile, Fewer Combination Liabilities
Two-Drug Combination Challenges
- Mismatched PK profiles require complex alignment
- Higher risk of drug-drug interactions
- Two agents, two doses, two schedules
- Higher potential of off-target effects
- Complex dosing coordination challenges
MTX-531 Single Molecule Advantages
- Coordinated PK profile across both targets
- Reduced risk of drug-drug interactions
- Streamlined single-agent dosing
- Lower potential for off-target effects
- Improved patient compliance and convenience
Learn More About Our Clinical Progress
Discover our development timeline and preclinical results
View Clinical Progress